scholarly journals Beta-Trace Protein as a Marker of Renal Dysfunction in Patients with Chronic Kidney Disease: Comparison with Other Renal Markers

2010 ◽  
Vol 29 (2) ◽  
pp. 66-72 ◽  
Author(s):  
Marijana Dajak ◽  
Svetlana Ignjatović ◽  
Biljana Stojimirović ◽  
Snežana Gajić ◽  
Nada Majkić-Singh
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Dysfunction ◽  
Cystatin C ◽  
Renal Diseases ◽  
Serum Cystatin C ◽  
Wide Range ◽  
Ckd Stage ◽  
Renal Markers ◽  
Spearman Test

Beta-Trace Protein as a Marker of Renal Dysfunction in Patients with Chronic Kidney Disease: Comparison with Other Renal MarkersBeta-trace protein (BTP), also known as prostaglandin D synthase, is a low-molecular-mass protein which belongs to the lipocalin protein family. It was found to be increased in the serum of patients with renal diseases. The aim of this study was to compare the clinical usefulness of serum levels of beta-trace protein for the detection of renal dysfunction in patients with chronic kidney disease (CKD) with levels of other renal markers: creatinine, cystatin C and β2-microglobulin (B2M). The study included 134 patients with a wide range of renal dysfunction that encompassed all five CKD stages. Obtained data showed that beta-trace protein highly correlated (Spearman test) with creatinine (r = 0.890), cystatin C (r = 0.904) and B2M (r = 0.933) and its levels in serum significantly increased from CKD stage 1 to 5. Furthermore, the values of glomerular filtration rate (GFR) estimated from a BTP-based formula significantly correlated with GFR calculated from creatinine-based and cystatin C-based formulas. ROC analyses showed that BTP had similar diagnostic accuracy for detection of reduced renal function in CKD stages as other renal markers, for estimated GFRs of < 30, < 60 and < 90 mL/min/1.73 m2. The areas under the ROC curves (AUC) for BTP, for these GFR limits, were from 0.983 to 0.917 and they were not significantly different from AUCs for other renal markers. The results of this study showed that BTP may be a useful and reliable serum marker for identifying the magnitude of renal dysfunction in patients with CKD and may have its place beside serum cystatin C and creatinine as an alternative endogenous GFR marker.

Measurements of serum cystatin C concentrations underestimate renal dysfunction in pediatric patients with chronic kidney disease

2011 ◽  
Vol 15 (4) ◽  
pp. 535-538 ◽  
Author(s):  
Osamu Uemura ◽  
Katsumi Ushijima ◽  
Takuhito Nagai ◽  
Takuji Yamada ◽  
Satoshi Yamakawa ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Dysfunction ◽  
Cystatin C ◽  
Pediatric Patients ◽  
Serum Cystatin C ◽  
Serum Cystatin

P0737THE ASSOCIATION BETWEEN CYSTATIN C AND ARTERIAL STIFFNESS IN NON-CKD PATIENTS

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Nejc Piko ◽  
Tadej Petreski ◽  
Robert Ekart ◽  
Radovan Hojs ◽  
Sebastjan Bevc
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Myocardial Perfusion ◽  
Arterial Stiffness ◽  
Arterial Hypertension ◽  
Cystatin C ◽  
Laboratory Data ◽  
Applanation Tonometry ◽  
Serum Cystatin C

Abstract Background and Aims Serum cystatin C (cysC) is produced by all nucleated cells at a constant rate, is filtered freely by the glomerulus and metabolized after tubular reabsorption. It is influenced less by age, gender and muscle mass compared to serum creatinine. These properties make it an important marker in detecting renal impairment. Arterial stiffness is a hallmark of atherosclerosis and is connected to cardiovascular events and mortality. In patients with chronic kidney disease (CKD), cysC correlates with increased arterial stiffness, but less is known about the association between cysC and arterial stiffness in non-CKD patients. Method The study was performed at the University Medical Centre Maribor between October 1st 2018 and January 1st 2020. Basic demographic and laboratory data were recorded. To estimate glomerular filtration rate (eGFR), Chronic Kidney Disease Epidemiology (CKD-EPI) equation was used. Patients with previously diagnosed CKD and/or eGFR ≤ 60 ml/min/1.73m2 at the time of admission, known malignancy, thyroid disease and/or on steroid therapy were not enrolled in the study. Arterial stiffness was measured with applanation tonometry (Sphygmocor®, Australia), carotid-femoral pulse wave velocity (cfPWV) was used as the gold standard of central arterial stiffness and subendocardial viability ratio (SEVR) was used as the marker of myocardial perfusion. SPSS® version 22 was used for statistical analysis. Results 111 patients (65.8% male, average age 64.3±9.4 years) were included in our study. Most common comorbidities were arterial hypertension (n=86, 77.5%), hyperlipidaemia (n=64, 57.7%) and diabetes mellitus (n=22, 19.8%). Mean creatinine value was 77.7±13.8 μmol/L (range 49-108 μmol/L), mean eGFR was 81.3±9.4 ml/min/1.73m2 (range 62-90 ml/min/1.73m2) and mean value of cysC was 0.94±0.18 mg/L (range 0.67-1.63 mg/L). Mean SEVR value was 165.7±36.1% (range 92-299%) and mean cfPWV value was 10.1±2.4 m/s (range 6.2-16.8 m/s). Significant correlation was found between cysC and SEVR (r=-0.316, p&lt;0.001) and between cysC and cfPWV (r=0.472, p&lt;0.001). Multiple regression analysis of arterial stiffness indices and cysC, age, gender, diabetes mellitus, arterial hypertension, eGFR and hyperlipidemia, showed statistically significant association between cysC and cfPWV (ß=0.220, p=0.038) and cysC and SEVR (ß=-0.278, p=0.017). Conclusion Serum cysC is independently associated with increased arterial stiffness, reduced myocardial perfusion and increased cardiovascular risk in non-CKD patients.

scholarly journals Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) Cystatin C Equations for Estimating GFR With Standardized Serum Cystatin C Values

2011 ◽  
Vol 58 (4) ◽  
pp. 682-684 ◽  
Author(s):  
Lesley A. Inker ◽  
John Eckfeldt ◽  
Andrew S. Levey ◽  
Catherine Leiendecker-Foster ◽  
Gregory Rynders ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Cystatin C ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Disease Epidemiology

scholarly journals Thrombomodulin as a New Marker of Endothelial Dysfunction in Chronic Kidney Disease in Children

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Dorota Drożdż ◽  
Monika Łątka ◽  
Tomasz Drożdż ◽  
Krystyna Sztefko ◽  
Przemko Kwinta
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Endothelial Dysfunction ◽  
Kidney Disease ◽  
Cystatin C ◽  
Oxidized Ldl ◽  
Left Ventricular ◽  
Intercellular Adhesion Molecule ◽  
Oxidative Stress Biomarkers ◽  
Ckd Stage

Endothelial dysfunction (ED) and oxidative stress are potential new pathomechanisms of cardiovascular diseases in patients with chronic kidney disease (CKD). The aim of the study was to assess the association between endothelial dysfunction, oxidative stress biomarkers, and cardiovascular risk factors in children with CKD. Serum oxidized LDL (oxLDL), protein carbonyl group, urea, creatinine, cystatin C, thrombomodulin, asymmetric dimethylarginine (ADMA), von Willebrand factor, brain natriuretic peptide (BNP), lipids, high sensitivity C-reactive protein, intercellular adhesion molecule-1 levels, and albuminuria were measured. Anthropometric, ambulatory blood pressure (BP) measurements and echocardiography were performed. The studied group consisted of 59 patients aged 0.7–18.6 (mean 11.1) years with stages 1 to 5 CKD. Thrombomodulin strongly correlated with creatinine (R=0.666; p<0.001), cystatin C (R=0.738; p<0.001), BNP (R=0.406; p=0.001), ADMA (R=0.353; p=0.01), oxLDL (R=0.340; p=0.009), 24-hour systolic (R=0.345; p=0.011) and mean (R=0.315; p<0.05) BP values, and left ventricular mass index (LVMI, R=0.293; p=0.024) and negatively with estimated glomerular filtration rate (R=−0.716; p<0.001). In children with CKD, TM strongly depended on kidney function parameters, oxLDL levels, and 24-hour systolic and mean BP values. Thrombomodulin seems to be a valuable marker of ED in CKD patients, correlating with CKD stage as well as oxidative stress, BP values, and LVMI.

scholarly journals Serum Cystatin C - Marker of Inflammation and Cardiovascular Morbidity in Chronic Kidney Disease Stages 1-4

2015 ◽  
Vol 27 (2) ◽  
pp. 75 ◽  
Author(s):  
Alma Muslimovic ◽  
Denijal Tulumovic ◽  
Senad Hasanspahic ◽  
Aida HamzicMehmedbasic ◽  
Ramajana Temimovic
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Cystatin C ◽  
Cardiovascular Morbidity ◽  
Serum Cystatin C ◽  
Serum Cystatin ◽  
Disease Stages

scholarly journals Pediatric chronic kidney disease rates in Southern Israel are higher than reported

F1000Research ◽  
2013 ◽  
Vol 2 ◽  
pp. 186
Author(s):  
Daniel Landau ◽  
Ruth Schreiber ◽  
Anya Kleinman ◽  
Alina Vodonos ◽  
Hannah Shalev
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Obstructive Uropathy ◽  
Pediatric Nephrology ◽  
Developed Countries ◽  
Renal Diseases ◽  
Disease Rates ◽  
Ckd Stage ◽  
Stage 1 ◽  
Diagnosis Age

Background: The incidence and prevalence of pediatric chronic kidney disease (p-CKD) in developed countries has previously been estimated to be 12 and 75 cases/106 population respectively, much lower than reports in young adults (age 20-40) (40,000/106). Thus, the extent of p-CKD may be underestimated.Methods: Being the only Pediatric Nephrology center in Southern Israel, we reviewed all detected cases of p-CKD (stages 1-5) between 1994-2008. We then prospectively summarized the incidence and prevalence of CKD between 2009-2010. Results: We retrospectively identified 192 children (53.9% of Bedouin origin, 53.4% males, median diagnosis age: 1 year) with CKD. The prevalence in December 2008 was 795 cases/106 for all CKD stages and 331/106 for CKD stage >2. Calculated incidence for the study period (1994-2008) was 46/106/year. The main CKD etiologies were: hypodysplasia: 35%; obstructive uropathy: 13%; genetic renal diseases: 28% and glomerulonephritis: 15%. The proportions of children in each CKD stage were as follows: stage 1: 50%; stages 2-4: 30%; stage 5: 20%. During a subsequent two-year study period we identified 26 new CKD cases (incidence: 54 cases/106/year). Conclusions: p-CKD rates in our area are higher than reported and maybe even higher if asymptomatic populations are screened. Fifty percent of detected cases have CKD stage 1. This may contribute significantly to CKD beyond the pediatric age.

Sign in / Sign up

Export Citation Format

Share Document